Siegfried, a pharmaceutical company that offers and manufactures primary and secondary drug substances and products, agreed to acquire a majority stake in DiNAMIQS, a company focused on the development and manufacturing of viral vectors for cell and gene therapies, from DiNAQOR. Financial terms were not disclosed. "With this acquisition, we are entering the rapidly growing space of cell and gene therapies where viral vector-based technologies support the majority of clinical candidates in a rich development pipeline. In our view, this approach of an initial small-scale acquisition of a highly capable technology platform followed by flexible bolt-on investments into capabilities and capacities in line with actual market needs, provides significant value upside at reasonable entry costs. This is perfectly in line with our strategy EVOLVE and our track record of disciplined execution of value-adding M&A – and a further step towards our vision of creating a leading CDMO in our space," Wolfgang Wienand, Siegfried CEO.